LncRNA DNAJC3-AS1 Promotes Hepatocellular Carcinoma (HCC) Progression via Sponging Premature miR-27b

References

• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y31439937
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13.
   PubMed Web of Science ®Google Scholar
• Liu P, Xie SH, Hu S, et al. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. Oncotarget. 2017;8(40):68131–68137. doi:10.18632/oncotarget.1924528978103
   PubMedGoogle Scholar
• Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67(2):302–309. doi:10.1016/j.jhep.2017.03.01128336466
   PubMed Web of Science ®Google Scholar
• Beal EW, Tumin D, Kabir A, et al. Trends in the mortality of hepatocellular carcinoma in the United States. J Gastrointest Surg. 2017;21(12):2033–2038. doi:10.1007/s11605-017-3526-728785936
   PubMed Web of Science ®Google Scholar
• Ganne-Carrié N, Chaffaut C, Bourcier V, et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol. 2018;69(6):1274–1283. doi:10.1016/j.jhep.2018.07.02230092234
   PubMed Web of Science ®Google Scholar
• Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes, mechanism of progression and biomarkers. Curr Chem Genom Transl Med. 2018;12(1):9–26. doi:10.2174/221398850181201000930069430
   PubMedGoogle Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.2908628130846
   PubMed Web of Science ®Google Scholar
• Daher S, Massarwa M, Benson AA, Khoury T. Current and future treatment of hepatocellular carcinoma: an updated comprehensive review. J Clin Transl Hepatol. 2018;6(1):69–78. doi:10.14218/JCTH.2017.0003129607307
   PubMed Web of Science ®Google Scholar
• Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol. 2019;9(2):221–232. doi:10.1016/j.jceh.2019.01.00431024205
   PubMed Web of Science ®Google Scholar
• Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatol Res. 2018;48(8):597–607. doi:10.1111/hepr.1318129689631
   PubMed Web of Science ®Google Scholar
• Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma. 2017;4:93–103. doi:10.2147/JHC.S10652928744453
   PubMed Web of Science ®Google Scholar
• Dai M, Chen S, Wei X, et al. Diagnosis, prognosis and bioinformatics analysis of lncRNAs in hepatocellular carcinoma. Oncotarget. 2017;8(56):95799–95809. doi:10.18632/oncotarget.2132929221168
   PubMedGoogle Scholar
• Xue C, Zhao Y, Jiang J, Li L. Expression levels of lncRNAs are prognostic for hepatocellular carcinoma overall survival. Am J Transl Res. 2020;12(5):1873–1883.32509183
   PubMed Web of Science ®Google Scholar
• Tang Y, Tang R, Tang M, et al. LncRNA DNAJC3-AS1 regulates fatty acid synthase via the EGFR pathway to promote the progression of colorectal cancer. Front Oncol. 2020;10:604534. doi:10.3389/fonc.2020.60453433604287
   PubMed Web of Science ®Google Scholar
• Na XY, Hu XQ, Zhao Y, Hu CH, Shang XS. LncRNA DNAJC3-AS1 functions as oncogene in renal cell carcinoma via regulation of the miR-27a-3p/PRDM14 axis. Eur Rev Med Pharmacol Sci. 2021;25(3):1291–1301.33629299
   PubMed Web of Science ®Google Scholar
• Liang R, Liu Z, Chen Z, et al. Long noncoding RNA DNAJC3-AS1 promotes osteosarcoma progression via its sense-cognate gene DNAJC3. Cancer Med. 2019;8(2):761–772. doi:10.1002/cam4.195530652414
   PubMed Web of Science ®Google Scholar
• Zhang J, Hua X, Qi N, et al. MiR-27b suppresses epithelial-mesenchymal transition and chemoresistance in lung cancer by targeting snail1. Life Sci. 2020;254:117238. doi:10.1016/j.lfs.2019.11723831887300
   PubMed Web of Science ®Google Scholar
• Hannafon BN, Cai A, Calloway CL, et al. miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study. BMC Cancer. 2019;19(1):642. doi:10.1186/s12885-019-5839-231253120
   PubMed Web of Science ®Google Scholar
• Chaiboonchoe A, Khraiwesh B, Murali C, et al. Safranal induces DNA double-strand breakage and ER-stress-mediated cell death in hepatocellular carcinoma cells. Sci Rep. 2018;8(1):16951. doi:10.1038/s41598-018-34855-030446676
   PubMed Web of Science ®Google Scholar
• Ashktorab H, Soleimani A, Singh G, et al. Saffron: the golden spice with therapeutic properties on digestive diseases. Nutrients. 2019;11(5):943. doi:10.3390/nu11050943
   PubMed Web of Science ®Google Scholar
• Amin A, Mahmoud-Ghoneim D. Texture analysis of liver fibrosis microscopic images: a study on the effect of biomarkers. Acta Biochim Biophys Sin (Shanghai). 2011;43(3):193–203. doi:10.1093/abbs/gmq12921258076
   PubMed Web of Science ®Google Scholar
• Hamza AA, Heeba GH, Hamza S, et al. Standardized extract of ginger ameliorates liver cancer by reducing proliferation and inducing apoptosis through inhibition oxidative stress/inflammation pathway. Biomed Pharmacother. 2021;134:111102. doi:10.1016/j.biopha.2020.11110233338743
   PubMed Web of Science ®Google Scholar
• Amin A, AlMansoori A, Baig B. Safranal-sorafenib combination therapy for liver cancer. U.S. Patent 10,568,873; 2020.
   Google Scholar
• Amin A, Awad B. Crocin-sorafenib combination therapy for liver cancer. U.S. Patent 10,933,076; 2021.
   Google Scholar
• Amin A. Prevention of liver cancer with safranal-based formulations. U.S. Patent 10,912,741; 2021.
   Google Scholar